Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mt. Sinai researchers report that aspirin reduces risk of first heart attack by one-third

23.09.2003


Aspirin reduces the risk of a first heart attack by 32 percent, according to a report by researchers at Mount Sinai Medical Center & Miami Heart Institute (MSMC-MHI) published in the current issue of Archives of Internal Medicine. The paper, which is based on a meta-analysis of five major randomized clinical trials (55,580 participants, 11,466 women) in primary prevention, also found that aspirin reduces the combined risk of heart attack, stroke and vascular death by 15 percent.



Charles H. Hennekens, M.D., Co-Director of Cardiovascular Research at MSMC-MHI, and Professor of Medicine & Epidemiology and Public Health at the University of Miami School of Medicine was the first to demonstrate the benefit of aspirin in reducing the risk of a first heart attack in a landmark Physicians’ Health Study (PHS), which was published in 1988 in the New England Journal of Medicine. Under his direction, Rachel S. Eidelman, M.D., a cardiology fellow at MSMC-MHI, performed the latest meta-analysis.

The findings strongly support the treatment guidelines issued by the American Heart Association (AHA), which recommends the use of aspirin for all men and women whose 10-year risks of a first coronary event are 10 percent or greater. The U.S. Preventive Services Task Force (USPSTF) released similar guidelines earlier in 2002, urging all healthcare providers to consider the use of aspirin in all apparently healthy men and women with a 6 percent or greater 10-year risk of a coronary event.


"The individual trials and their meta-analysis support the AHA and USPSTF guidelines, which note that the benefits of long-term aspirin use are likely to outweigh any risks for these individuals," Hennekens said. "The more widespread and appropriate use of aspirin in primary prevention could avoid hundreds of thousands of first heart attacks and important vascular events each year in the U.S."

The aspirin component of Dr. Hennekens trial, the PHS, was terminated early on January 25, 1988 based on the unanimous recommendations of the Data and Safety Monitoring Board, due primarily to a statistically extreme 44 percent reduction in risk of a first heart attack among those assigned at random to aspirin. There have been four primary prevention trials published since then, three of which showed similar positive findings for aspirin.

"We found that the current totality of evidence strongly supports our initial findings from the Physicians’ Health Study that aspirin significantly reduces the risk of a first heart attack in apparently healthy individuals," Hennekens added. "This data, along with the findings that aspirin reduces the risk of death by 23 percent if given during a heart attack and by 15 percent in a wide range of people who have survived prior cardiovascular events, demonstrate the need for wider utilization of aspirin."

"Yet despite the clearly demonstrated cardio-protective benefits of aspirin, this medication remains alarmingly underutilized among survivors of prior events, those having a heart attack and apparently healthy men and women, whose 10-year risk is 10 percent or more," Hennekens continued. "We hope the latest findings result in greater awareness on the part of healthcare providers and the general public and motivate increased aspirin utilization, which could result in significant reductions of premature cardiovascular deaths and first heart attacks."

Coronary heart disease is the single leading cause of death in the United States, accounting for more than 500,000 deaths annually. Approximately 80 percent of deaths from coronary heart disease in people under age 65 occur during the first heart attack.



Mount Sinai & Miami Heart’s Cardiovascular Center of Excellence is committed to being a leader in the prevention, diagnosis and treatment of heart disease. The medical center is the largest cardiac services provider in South Florida, conducting approximately 1,300 open heart procedures and approximately 7,400 diagnostic and therapeutic cardiac catheterizations annually.

For a physician referral, please call (305) 674-2273

Katie Cline | EurekAlert!

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>